Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

This study has been completed.
Sponsor:
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00192309
First received: September 12, 2005
Last updated: February 13, 2012
Last verified: February 2012
  Purpose

The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A & B, live, cold-adapted (liquid formulation CAIV-T; Wyeth, Marietta, PA).


Condition Intervention Phase
Influenza
Biological: CAIV-T
Biological: TIV
Biological: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Kinetics of the hemagglutination inhibition antibody response to each vaccine strain [ Time Frame: Day 0-28 ] [ Designated as safety issue: No ]
    The geometric mean titers for each strain between Day 0 and 28 were examined.


Secondary Outcome Measures:
  • Expression of IgA in nasal wash and saliva swab samples [ Time Frame: Days 0-28 ] [ Designated as safety issue: No ]
    Nasal wash and saliva swab IgA antibody titers were expressed as the ratio of specific to total IgA.

  • Expression of B-cells in peripheral blood [ Time Frame: Days 0-28 ] [ Designated as safety issue: No ]
    The B-cell ELISPOT assays are designed to detect B-cells in the peripheral blood that are actively secreting influenza strain-specific IgG or IgA antibody.

  • Number of CD3+ peripheral blood mononuclear cells secreting interferon gamma [ Time Frame: Days 0-28 ] [ Designated as safety issue: No ]
    The number of CD3+ peripheral blood mononuclear cells (PBMCs), i.e., T-cells, secreting IFN-γ prior to and after vaccination following in vitro stimulation of these cells using the IFN-γ ELISPOT assay.

  • Number of subjects with local reactions [ Time Frame: Days 0-7 ] [ Designated as safety issue: Yes ]
    Local injection site reactions were collected from subjects in the TIV treatment group only.

  • Number of subjects with systemic reactions [ Time Frame: Days 0-7 ] [ Designated as safety issue: Yes ]
    Each study subject collected prompted reactogenicity events on a diary card worksheet for 7 days (study days 0 - 6) following vaccination.

  • Number of subjects with adverse events [ Time Frame: Days 0-7 ] [ Designated as safety issue: Yes ]
    An Adverse Event (or Adverse Experience, AE) was any untoward, undesired or unexpected clinical event in the form of signs, symptoms, disease or laboratory or physiological observations occurring (in a human being) in a temporal relationship to the use of a WLV product, regardless of causal relationship.


Enrollment: 31
Study Start Date: September 2001
Study Completion Date: December 2001
Primary Completion Date: December 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cold-adapted influenza vaccine (CAIVT)
A single intranasal dose of 10^7 fluorescent focus units.
Biological: CAIV-T
Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
Other Name: FluMist
Active Comparator: Trivalent inactivated vaccine (TIV)
A single dose of commercially available Flushield was administered intramuscularly.
Biological: TIV
TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
Other Name: Flushield
Placebo Comparator: Placebo
The 0.2 mL administered intranasally.
Biological: Placebo
Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

Detailed Description:

This was a randomized, open-label, placebo-controlled, outpatient study carried out in healthy adults 18 to < 65 years of age. The study was designed to evaluate the kinetics of the immune responses generated by each of the study products in order to determine the best sampling time for future studies. Subjects were randomized in a 1:1:1 ratio to receive a single dose of either CAIV-T, inactivated influenza virus vaccine (TIV), or placebo.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects had to have been at least 18 years of age and less than 65 years of age at the time informed consent was obtained;
  • Women of child-bearing potential had to use reliable methods of hormonal and/or nonhormonal contraception (which includes cervical cap, diaphragm, condoms with spermicide or IUD) during sexual intercourse throughout the entire study period; a negative urine pregnancy test (with detection limit of less than or equal to 25mIU/mL) no more than 24 hours prior to vaccine administration; and agreed to avoid pregnancy during participation in the study. A urine pregnancy test was also conducted at the completion of study participation. Females who were surgically sterile at time of enrollment were not required to undergo pregnancy testing.
  • who were determined by medical history, physical examination and clinical judgement to be eligible for the study.
  • who provided written informed consent after the nature of the study has been explained;
  • who were available for one month duration of the trial (from enrollment to study completion);
  • who could be reached by study staff for the post-vaccination contact [telephone, clinic or home visit].

Exclusion Criteria:

  • who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
  • with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids and intranasal steroids; or cytotoxic agents;
  • who had an immunosuppressed or an immunocompromised individual living in the same household;
  • who had a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo;
  • who received any commercially-available or investigational injected influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment;
  • who previously received an intranasally administered influenza vaccine;
  • who had any medical conditions that, in the opinion of the investigator, might interfere with interpretation of the study results;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192309

Locations
United States, Connecticut
David M. Radin, MD
Stamford, Connecticut, United States, 06905
Sponsors and Collaborators
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Principal Investigator: Robert Walker, MD MedImmune LLC
  More Information

No publications provided

Responsible Party: Raburn Mallory, MD/ Sr Dir Clinical Development, MedImmune
ClinicalTrials.gov Identifier: NCT00192309     History of Changes
Other Study ID Numbers: D153 P004
Study First Received: September 12, 2005
Last Updated: February 13, 2012
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 21, 2014